Constellation Brands' Beer, Cannabis Bets Make It an Intoxicating Stock Pick –

What’s better than a cold one after a long day? A beer-focused stock with room to grow.

Enter Action Alerts PLUS holding Constellation Brands Inc. (STZ) . The company recently trimmed expectations for its wine sales growth to low single digits, but according to Macquarie, this more realistic expectation leaves shares “undemanding” relative to earnings growth forecasts.

In the Feb. 22 note, Macquarie analyst Caroline Levy said she expects earnings over the next three years to grow at an average of 13% on organic sales gains of 7%.

Beer growth in fiscal 2019 will be driven by continued distribution gains at retail, more sales of cans and draught and the “well-supported” launch of Corona Premier and new packaging for Corona Familiar.

“In addition to the well-broadcast Corona Premier and Familiar launches, STZ will announce two new, alternative beverage alcohol (ABA) products at its Gold Network Summit in two weeks. Additionally, it has plans for a new domestic super-premium product within the year,” Levy wrote.

But beyond its strong, growing beer portfolio, Constellation made a bold entry into a burgeoning market: legal cannabis. In October, the company agreed to acquire a minority stake in Canopy Growth Corp., an Ontario-based medicinal cannabis products provider.

Macquarie noted that about $10 million of Constellation’s estimated $35 million tax reform-related cash benefit will go toward cannabis product development, which gives the company a “first-mover advantage in this nascent market,” analysts said.

So why does a cannabis play make sense for a spirits maker Constellation?

Cannabis is set for federal legality in Canada in July, and Constellation “expects that beverages will be legal soon thereafter,” said Bill Newlands, president and operating chief, at a conference in New York this week.

“This past year, we brought 40% — 40% of the total growth at retail in the

Read More Here...